Ikonisys

Ikonisys Intangible Assets

The Intangible Assets of Ikonisys (ALIKO.PA) as of Oct 21, 2026 is 3.95 M EUR. In the previous year, Intangible Assets was 4.81 M EUR — a change of -17.78% (lower).

Intangible Assets

3.95 MEUR

YoY

-17.78%

Last updated:

Intangible Assets of Ikonisys is 2023 3.95 M EUR. Intangible Assets of Ikonisys was 2022 4.81 M EUR. It decreases by -17.78% lower compared to the previous year.

The Ikonisys Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2019
7.91 M EUR
Jan 1, 2020
8.00 M EUR
Jan 1, 2021
4.43 M EUR
Jan 1, 2022
4.81 M EUR
Jan 1, 2023
3.95 M EUR
The Ikonisys Intangible Assets history
YEARIntangible AssetsYoY
3.95 MEUR-17.78%
4.81 MEUR+8.53%
4.43 MEUR-44.67%
8.00 MEUR+1.20%
7.91 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ikonisys Stock analysis

What does Ikonisys do? Ikonisys SA generates revenue through the sale of its cell diagnostic products, including oncoFISH bladder, oncoFISH her2, oncoFISH cervical, oncoFISH PTEN, oncoFISH ALK, and Explorer applications. These products are designed for cancer diagnosis, genetic disorder detection, and fertility testing, utilizing advanced molecular and immunological markers. The company's target customers are healthcare providers and clinical laboratories seeking accurate rare cell detection solutions. Ikonisys SA's offerings are tailored to specific medical applications such as bladder, breast, cervical, prostate, lung, and hematological cancer diagnostics, leveraging its proprietary Ikoniscope robotic components and digital microscope technology. The firm's product portfolio focuses on specialized diagnostic applications, with oncoFISH solutions targeting specific cancer types through molecular marker analysis. Explorer applications support hematological cancer diagnostics, while the underlying technology combines image acquisition, software engine, and digital microscopy for reliable cell detection. Ikonisys SA serves the healthcare sector by providing tools that enable precise diagnosis of genetic conditions and cancer types through its unique cellular analysis platform. Ikonisys SA's revenue streams are derived from the distribution of its diagnostic applications to clinical settings. The company's products are sold to healthcare institutions requiring advanced diagnostic capabilities for cancer, genetic disorders, and fertility issues. By offering targeted solutions like oncoFISH bladder for bladder cancer and oncoFISH her2 for breast cancer, Ikonisys SA addresses specific diagnostic needs within the medical field, utilizing its proprietary technology stack including Ikoniscope components and digital microscopy. Ikonisys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ikonisys stock

Intangible Assets of Ikonisys is 3.95 M EUR in 2023.

Intangible Assets of Ikonisys changed from 4.81 M EUR to 3.95 M EUR, representing a -17.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Ikonisys since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Ikonisys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ikonisys

All Key Metrics — Ikonisys